Communications







  • Stendhal’s Strategic Alliance with Adienne

    Stendhal’s Strategic Alliance with Adienne
    26/01/2023

    Stendhal grows its portfolio of cancer therapies through an alliance with Adienne.
    With the innovative delivery system TEPADINA®, cancer patients will be able to be treated outside health centers in the future.

  • Stendhal-Nutricia Alliance Statement

    Stendhal-Nutricia Alliance Statement
    01/10/2022

    Stendhal announces a strategic partnership with Nutricia to market nutritional solutions in Mexico.

  • Stendhal recognized as an Ethical Company

    Stendhal recognized as an Ethical Company
    01/09/2022

    Stendhal was recognized within the Top 15 in the ranking of the Most Ethical Companies in Mexico.

  • Stendhal Innovation Week Statement

    Stendhal Innovation Week Statement
    01/05/2022

    Due to the pandemic, Mexicans will have faster access to innovative therapies.

  • Stendhal-Alnylam Statement

    Stendhal-Alnylam Statement
    15/03/2022

    Stendhal and Alnylam announce a strategic alliance to offer RNAi therapies in Mexico, Costa Rica, Guatemala, Panama, and the Dominican Republic.

  • Stendhal recognized as "Empresa de Diez" by INFONAVIT

    Stendhal recognized as "Empresa de Diez" by INFONAVIT
    08/01/2022

    The pharmaceutical company Stendhal and its general director Rodrigo Ruiz received the insignia of "Empresa de Diez" (Company Excellency) granted by INFONAVIT.

  • Rodrigo Ruiz re-elected President of AMIIF

    Rodrigo Ruiz re-elected President of AMIIF
    01/01/2022

    Rodrigo Ruiz Mingramm, COO of Stendhal, will continue as President of the AMIIF for a second period.

  • Detect the first silent symptoms caused by Arterial Hypertension

    Detect the first silent symptoms caused by Arterial Hypertension
    20/09/2021

    In order to support the well-being and health of Mexicans, Stendhal shares the different symptoms to detect high blood pressure in time and provide effective therapy at the right time.

  • Migraine Bulletin

    Migraine Bulletin
    31/08/2021

    Migraine is a neurovascular disorder that affects more than one billion people worldwide, making it the second leading cause of disability in people under the age of 50.

  • Epilepsy Bulletin

    Epilepsy Bulletin
    24/01/2021

    Stendhal helps you spot the signs that your child may have epilepsy.

  • Blue Monday Media Alert

    Blue Monday Media Alert
    18/01/2021

    January 18 is the saddest day of the year; identify whether it is temporary or it could be depression.

  • Stendhal-BioMarin Statement

    Stendhal-BioMarin Statement
    01/01/2021

    Stendhal strengthens its portfolio of rare disease therapies in partnership with North American laboratory BioMarin.

  • Valdoxa

    Valdoxa
    04/11/2020

    Stendhal offers Agomelatine, an effective and unique molecule that helps in the treatment of moderate to severe depression.

  • Stendhal treatment for the reduction and control of cardiovascular risk

    Stendhal treatment for the reduction and control of cardiovascular risk
    28/09/2020

    Stendhal offers the Mexican population a treatment to reduce and control cardiovascular risk.



Logo Stendhal

Tel. +(52) 55 2000 66 30
Address: Camino a Santa Teresa No. 1040, Mezzanine 1, Col. Jardines en la Montaña,
Alcaldía Tlalpan, C.P. 14210, Ciudad de México, México

© Stendhal International 2024. All Rights Reserved. Stendhal Pharma is owned by Específicos Stendhal, S.A. de C.V.